Serina Therapeutics director granted 7,553 shares

Serina Therapeutics, Inc. director Venkatesan Jay reported an acquisition of 7,553 shares of common stock.

Rhea-AI Filing Summary

Serina Therapeutics, Inc. director Venkatesan Jay reported an acquisition of 7,553 shares of common stock. These shares were issued at $1.94 per share as a grant classified as a “grant, award, or other acquisition.”

According to a footnote, the common shares were issued as payment of accrued dividends on the reporting individual’s A Convertible Preferred Stock issued on April 8, 2025. Following this non-cash dividend payment in stock, Jay directly holds 7,553 common shares.

Insider Trade Summary

Grant/Award: 7,553 shares

Grant/Award 1 txn

Insider Venkatesan Jay

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,553	$1.94	$15K

Holdings After Transaction: Common Stock — 7,553 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were issued for payment of accrued dividends on the reporting individuals A Convertible Preferred Stock issued on April 8, 2025.

Key Figures

Shares acquired: 7,553 shares Grant value per share: $1.94 per share Total shares held after transaction: 7,553 shares

3 metrics

Shares acquired 7,553 shares Common stock grant on March 31, 2026

Grant value per share $1.94 per share Value used for the common stock issuance

Total shares held after transaction 7,553 shares Director’s direct common stock holdings following grant

Key Terms

Grant, award, or other acquisition, accrued dividends, A Convertible Preferred Stock

3 terms

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

accrued dividends financial

"shares of common stock were issued for payment of accrued dividends on the reporting"

Accrued dividends are payments a company owes to shareholders that have been earned or officially declared but not yet paid; think of them as an IOU the company has for past dividend obligations. They matter to investors because they represent a near-term claim on a company’s cash, affect the company’s reported liabilities and value, and can be especially important when assessing income reliability or priority in a payout situation.

A Convertible Preferred Stock financial

"accrued dividends on the reporting individuals A Convertible Preferred Stock issued on April 8, 2025"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Serina Therapeutics (SER) report for Venkatesan Jay?

Serina Therapeutics reported that director Venkatesan Jay acquired 7,553 shares of common stock. The shares were issued at $1.94 each as a non-cash grant classified as a “grant, award, or other acquisition,” increasing his direct common stock holdings to 7,553 shares.

How many Serina Therapeutics (SER) shares does Venkatesan Jay hold after this Form 4?

After the reported transaction, Venkatesan Jay directly holds 7,553 shares of Serina Therapeutics common stock. All of these shares came from a single grant tied to accrued dividends on his A Convertible Preferred Stock, rather than an open-market purchase.

Was the Serina Therapeutics (SER) Form 4 transaction a market purchase or a grant?

The Form 4 transaction for Serina Therapeutics was a grant, not a market purchase. It is coded as an “A” transaction, meaning a grant, award, or other acquisition, with shares issued in payment of accrued dividends instead of being bought on the open market.

What price per share is shown in the Serina Therapeutics (SER) insider grant?

The reported transaction shows a price of $1.94 per share for the 7,553 common shares issued to director Venkatesan Jay. This figure reflects the value used in the filing for the non-cash stock issuance tied to accrued dividends on preferred stock.

What is the source of the shares issued to the Serina Therapeutics (SER) director?

The 7,553 common shares issued to the Serina Therapeutics director came from payment of accrued dividends. A footnote explains they were issued as payment of accrued dividends on the reporting individual’s A Convertible Preferred Stock that was issued on April 8, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 03:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venkatesan Jay

(Last) (First) (Middle)

601 GENOME WAY

SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		7,553(1)	A	$1.94	7,553	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were issued for payment of accrued dividends on the reporting individuals A Convertible Preferred Stock issued on April 8, 2025.

Remarks:

	/s/ Jay R. Venkatesan	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)